Avanir Pharma Settles NUEDEXTA Patent Litigation With Wockhardt

(RTTNews) - Avanir Pharmaceuticals, Inc. (AVNR) said Friday that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application seeking approval to market generic versions of Avanir's NUEDEXTA capsules.

The settlement agreement grants Wockhardt the right to begin selling a generic version of NUEDEXTA on July 30, 2026, or earlier under certain circumstances.

The parties have also agreed to file a stipulation and order of dismissal with the United States District Court for the District of Delaware which will conclude the litigation with respect to Wockhardt. The settlement does not end Avanir's ongoing litigation against the other two ANDA filers.

In compliance with U.S. law, the settlement agreement will be submitted to the U.S. Federal Trade Commission and the Department of Justice where it is subject to review.